PD-1/L1 immune checkpoint inhibitors for KRAS-mutant non-small cell lung cancer: a multicenter retrospective real-world study

Related articles

1. Differential Benefit of Immune Checkpoint Blockade by KRAS Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish Cohort

   This article has 8 authors:

   1. Ella A. Eklund
   2. Sama I. Sayin
   3. Jonas Smith Jonsson
   4. Hannes van Renswoude
   5. Jan Nyman
   6. Andreas Hallqvist
   7. Clotilde Wiel
   8. Volkan I. Sayin

2. Efficacy analysis and prognostic factors of first-line chemotherapy combined with immunotherapy in extensive-stage small cell lung cancer: a real-world study

   This article has 7 authors:

   1. Jian-Xi Zhou
   2. Yun-Chuan Sun
   3. Li Xiao
   4. Hong-Ling Lu
   5. Xiao-Ming Yin
   6. Kui Fan
   7. Ying-Nan Zhou

3. Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer

   This article has 18 authors:

   1. Natalie J. Miller
   2. Christina S. Baik
   3. Joel W. Neal
   4. Fangdi Sun
   5. Rafael Santana-Davila
   6. Sylvia Lee
   7. Keith D. Eaton
   8. Renato G. Martins
   9. Cristina Rodriguez
   10. Heather A. Wakelee
   11. Sukhmani K. Padda
   12. Eric Q. Konnick
   13. Alex Camai
   14. Tatyana Pisarenko
   15. Viswam S. Nair
   16. A. McGarry Houghton
   17. Shin-Heng Chiou
   18. Diane Tseng